Compound 2f (SARM) is a drug which acts as a selective androgen receptor modulator (SARM), originally developed by Takeda Pharmaceutical for the treatment of prostate cancer. It is a potent but tissue specific androgen agonist with an EC<sub>50</sub> of 4.7nM, producing anabolic effects on muscles and in the central nervous system but with little effect on the prostate gland, and inducing sexual behaviour in animal studies.